Eisai Partners with BlissBio to Jointly Develop ADC for Multiple Cancer Types
Eisai Co., Ltd. revealed that it has partnered with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. to develop BB-1701, an antibody-drug conjugate
Read moreEisai Co., Ltd. revealed that it has partnered with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. to develop BB-1701, an antibody-drug conjugate
Read moreBiosynth provides an exceptional range of chemicals, peptides and biochemicals, offering scientists and researchers worldwide unparalleled convenience, choice, and dependability.
Read moreAt the Edge of Innovation – Biosynth At the Edge of Innovation – Biosynth, is where Chemistry meets Biology, Products
Read moreCompugen will present new research at AACR 2023 that allows for the accurate detection and study of novel target PVRIG.
Read moreWith the 3-D Life Slow Gelling hydrogel kits, the set-up of 3D cell culture is easy. Growing cells in a
Read moreChicago Headquartered Tempus, pioneering AI-enabled precision medicine, has entered a third strategic collaboration with pharma giant Pfizer, aiming to gather
Read moreTransCode Therapeutics and BRAIN Biotech have entered a joint research and development agreement (JDA) with the objective to co-develop a
Read moreThe GERBU Adjuvant P TM is developed specifically for polyclonal antibody production. Containing non-hazardous immuno active components, this adjuvant is
Read moreQIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN, announced on Monday the launch of their enhanced QIAGEN CLC Genomics
Read moreModerna Inc will make investments in mRNA research and development (R&D) in the UK and construct a cutting-edge facility for
Read more